162 related articles for article (PubMed ID: 34073624)
1. Regulation of AMPK Activity by CRBN Is Independent of the Thalidomide-CRL4
Yang SJ; Jeon S; Baek JW; Lee KM; Park CS
Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34073624
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4.
Belair DG; Lu G; Waller LE; Gustin JA; Collins ND; Kolaja KL
Sci Rep; 2020 Feb; 10(1):2864. PubMed ID: 32071327
[TBL] [Abstract][Full Text] [Related]
3. Development of Phenyl-substituted Isoindolinone- and Benzimidazole-type Cereblon Ligands for Targeted Protein Degradation.
Nie X; Zhao Y; Tang H; Zhang Z; Liao J; Almodovar-Rivera CM; Sundaresan R; Xie H; Guo L; Wang B; Guan H; Xing Y; Tang W
Chembiochem; 2024 Feb; 25(4):e202300685. PubMed ID: 38116854
[TBL] [Abstract][Full Text] [Related]
4. Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma.
Charliński G; Vesole DH; Jurczyszyn A
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572892
[TBL] [Abstract][Full Text] [Related]
5. On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugs.
Heim C; Maiwald S; Steinebach C; Collins MK; Strope J; Chau CH; Figg WD; Gütschow M; Hartmann MD
Biochem Biophys Res Commun; 2021 Jan; 534():67-72. PubMed ID: 33310190
[TBL] [Abstract][Full Text] [Related]
6. A Degron Blocking Strategy Towards Improved CRL4
Bouguenina H; Scarpino A; O'Hanlon JA; Warne J; Wang HZ; Wah Hak LC; Sadok A; McAndrew PC; Stubbs M; Pierrat OA; Hahner T; Cabry MP; Le Bihan YV; Mitsopoulos C; Sialana FJ; Roumeliotis TI; Burke R; van Montfort RLM; Choudhari J; Chopra R; Caldwell JJ; Collins I
Chembiochem; 2023 Dec; 24(23):e202300351. PubMed ID: 37418539
[TBL] [Abstract][Full Text] [Related]
7. High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients.
Borsi E; Mazzocchetti G; Dico AF; Vigliotta I; Martello M; Poletti A; Solli V; Armuzzi S; Taurisano B; Kanapari A; Pistis I; Zamagni E; Tacchetti P; Pantani L; Mancuso K; Rocchi S; Rizzello I; Cavo M; Terragna C
Clin Exp Med; 2023 Dec; 23(8):5227-5239. PubMed ID: 37815734
[TBL] [Abstract][Full Text] [Related]
8. Cereblon influences the timing of muscle differentiation in
Long J; Mariossi A; Cao C; Mo Z; Thompson JW; Levine MS; Lemaire LA
Proc Natl Acad Sci U S A; 2023 Oct; 120(43):e2309989120. PubMed ID: 37856545
[TBL] [Abstract][Full Text] [Related]
9. Functional effects of a pathogenic mutation in Cereblon (CRBN) on the regulation of protein synthesis via the AMPK-mTOR cascade.
Lee KM; Yang SJ; Choi JH; Park CS
J Biol Chem; 2014 Aug; 289(34):23343-52. PubMed ID: 24993823
[TBL] [Abstract][Full Text] [Related]
10. Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide.
Furihata H; Yamanaka S; Honda T; Miyauchi Y; Asano A; Shibata N; Tanokura M; Sawasaki T; Miyakawa T
Nat Commun; 2020 Sep; 11(1):4578. PubMed ID: 32929090
[TBL] [Abstract][Full Text] [Related]
11. Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs.
Sperling AS; Burgess M; Keshishian H; Gasser JA; Bhatt S; Jan M; Słabicki M; Sellar RS; Fink EC; Miller PG; Liddicoat BJ; Sievers QL; Sharma R; Adams DN; Olesinski EA; Fulciniti M; Udeshi ND; Kuhn E; Letai A; Munshi NC; Carr SA; Ebert BL
Blood; 2019 Jul; 134(2):160-170. PubMed ID: 31043423
[TBL] [Abstract][Full Text] [Related]
12. Structural and biophysical comparisons of the pomalidomide- and CC-220-induced interactions of SALL4 with cereblon.
Ma X; Leon B; Ornelas E; Dovala D; Tandeske L; Luu C; Pardee G; Widger S; Solomon JM; Beckwith REJ; Moser H; Clifton MC; Wartchow CA
Sci Rep; 2023 Dec; 13(1):22088. PubMed ID: 38086859
[TBL] [Abstract][Full Text] [Related]
13. Structural rationalization of GSPT1 and IKZF1 degradation by thalidomide molecular glue derivatives.
Nowak RP; Che J; Ferrao S; Kong NR; Liu H; Zerfas BL; Jones LH
RSC Med Chem; 2023 Mar; 14(3):501-506. PubMed ID: 36970148
[TBL] [Abstract][Full Text] [Related]
14. Probing the CRL4
Righetto GL; Yin Y; Duda DM; Vu V; Szewczyk MM; Zeng H; Li Y; Loppnau P; Mei T; Li YY; Seitova A; Patrick AN; Brazeau JF; Chaudhry C; Barsyte-Lovejoy D; Santhakumar V; Halabelian L
PNAS Nexus; 2024 Apr; 3(4):pgae153. PubMed ID: 38665159
[TBL] [Abstract][Full Text] [Related]
15. Single-Domain Antibody-Based Protein Degrader for Synucleinopathies.
Jiang Y; Lin Y; Tetlow AM; Pan R; Ji C; Kong XP; Congdon EE; Sigurdsson EM
bioRxiv; 2024 Apr; ():. PubMed ID: 38558982
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma.
Amatangelo M; Flynt E; Stong N; Ray P; Van Oekelen O; Wang M; Ortiz M; Maciag P; Peluso T; Parekh S; van de Donk NWCJ; Lonial S; Thakurta A
Cell Rep Med; 2024 May; ():101571. PubMed ID: 38776914
[TBL] [Abstract][Full Text] [Related]
17. Thrombospondin-1 is an endogenous substrate of cereblon responsible for immunomodulatory drug-induced thromboembolism.
Hatakeyama K; Kikushige Y; Ishihara D; Yamamoto S; Kawano G; Tochigi T; Miyamoto T; Sakoda T; Christoforou A; Kunisaki Y; Fukata M; Kato K; Ito T; Handa H; Akashi K
Blood Adv; 2024 Feb; 8(3):785-796. PubMed ID: 38163319
[TBL] [Abstract][Full Text] [Related]
18. iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells.
Bouguenina H; Nicolaou S; Le Bihan YV; Bowling EA; Calderon C; Caldwell JJ; Harrington B; Hayes A; McAndrew PC; Mitsopoulos C; Sialana FJ; Scarpino A; Stubbs M; Thapaliya A; Tyagi S; Wang HZ; Wood F; Burke R; Raynaud F; Choudhary J; van Montfort RLM; Sadok A; Westbrook TF; Collins I; Chopra R
iScience; 2023 Jul; 26(7):107059. PubMed ID: 37360684
[TBL] [Abstract][Full Text] [Related]
19. Energy sensor AMPK gamma regulates translation via phosphatase PPP6C independent of AMPK alpha.
Zhou Q; Hao B; Cao X; Gao L; Yu Z; Zhao Y; Zhu M; Zhong G; Chi F; Dai X; Mao J; Zhu Y; Rong P; Chen L; Bai X; Ye C; Chen S; Liang T; Li L; Feng XH; Tan M; Zhao B
Mol Cell; 2024 May; 84(9):1816. PubMed ID: 38701743
[No Abstract] [Full Text] [Related]
20. Cereblon enhancer methylation and IMiD resistance in multiple myeloma.
Haertle L; Barrio S; Munawar U; Han S; Zhou X; Vogt C; Fernández RA; Bittrich M; Ruiz-Heredia Y; Da Viá M; Zovko J; Garitano-Trojaola A; Bolli N; Ruckdeschel A; Stühmer T; Chatterjee M; Kull M; Krönke J; Agirre X; Martin-Subero JI; Raab P; Einsele H; Rasche L; Martinez-Lopez J; Haaf T; Kortüm KM
Blood; 2021 Nov; 138(18):1721-1726. PubMed ID: 34115836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
